Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

NCT05651711 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05651711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05651711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
December 14, 2022
Completion date
August 27, 2024
Enrollment
726 (actual)
Sites
197

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis